In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells
1998

In vitro activity of aplidine, a new marine-derived anti-cancer compound

Sample size: 56 publication Evidence: moderate

Author Information

Author(s): H Depenbrock, R Peter, GT Faircloth, I Manzanares, J Jimeno, AR Hanauske

Primary Institution: Technische Universitat Munchen

Hypothesis

The study evaluates the antiproliferative effect of aplidine on freshly explanted human tumours and haematopoietic precursor cells.

Conclusion

Aplidine shows a concentration-dependent anti-tumour effect on various human tumour specimens.

Supporting Evidence

  • Aplidine showed a clear concentration-dependent anti-tumour effect in 49 evaluable specimens.
  • At 0.05 µM, 85% of the specimens were markedly inhibited.
  • Continuous exposure for 21-28 days in 54 tumour specimens also led to a concentration-dependent activity relationship.
  • Breast, melanoma, and non-small-cell lung cancer appear to be sensitive to low concentrations of aplidine.
  • The study indicates a therapeutic window at marginally myelotoxic concentrations.

Takeaway

Aplidine is a new medicine from the sea that helps fight cancer by stopping cancer cells from growing.

Methodology

The study used an in vitro cloning system with freshly explanted human tumours and evaluated the effects of aplidine on colony formation.

Limitations

The study primarily focuses on in vitro results, which may not fully translate to in vivo effectiveness.

Participant Demographics

The study involved freshly explanted human tumour specimens from various types of cancer.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication